KALA BIO, Inc. (KALA) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Cali Pharmaceuticals conference call to review its first quarter 2022 financial results. At this time, all participants are in listen-only mode. Following management's prepared remarks, a Q&A session will be held. As a reminder, this call is being recorded. I would now like to turn the call over to Jill Steyer, Executive Director, Investor Relations and Corporate Communications for Cali Pharmaceuticals. Please proceed. Thank you, Operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwiki, Chief Executive Officer, Todd Basemore, President and Chief Operating Officer, Kim Brazel, Head of R&D and Chief Medical Officer, Mary Remus, Chief Financial Officer, and Darius Karabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call. During this call, we will make certain comments about CALA's future expectations, plans, and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include observations associated with our commercialization of ISUVIS and INVELTUS, statements regarding the development, program, and market potential of KPI 012, and the sufficiency of our cash resources. These and other forward-looking statements are based on the beliefs and expectations of management as of this conference call. Our actual results may differ materially from our expectations. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances that occur after this conference call, except as required by law. Investors should carefully read the risks and uncertainties described in today's press release. as well as the risk factors wh...